Aurinia Pharmaceuticals Inc Sustainability Reports

Aurinia Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering therapies for people living with autoimmune diseases. Its flagship commercial product is LUPKYNIS (voclosporin), the first FDA-approved oral therapy for adult patients with active lupus nephritis.

Sector: Manufacturing

Country: Canada

Exchange: Nasdaq

LEI: 5299008YP2BW4570ML28

FIGI: BBG001S68013

5 reports from 2022 to 2025

• Aurinia Pharmaceuticals Inc 2025 Forced Labour and Child Labour Report
• Aurinia Pharmaceuticals Inc 2024 Forced Labour and Child Labour Report
• Aurinia Pharmaceuticals Inc 2023 Form 10-K
• Aurinia Pharmaceuticals Inc 2023 ESG Report
• Aurinia Pharmaceuticals Inc 2022 ESG Report